Cost-Utility Analysis of Transcatheter Aortic Valve Implantation versus Surgery in High-Risk Severe Aortic Stenosis Patients in Thailand.
Unchalee PermsuwanVoratima YoodeeWacin BuddhariNattawut WongpraparutTasalak ThonghongSirichai CheewatanakornkulKrissada MeemookPranya SakiyalakPongsanae DuangpakdeeJirawit YadeePublished in: ClinicoEconomics and outcomes research : CEOR (2022)
TAVI is not a cost-effective strategy in patients with severe AS who are at high surgical risk when compared to SAVR at the WTP of THB 160,000/QALY (USD 4884/QALY) from the perspectives of society and the healthcare system.
Keyphrases
- aortic stenosis
- transcatheter aortic valve implantation
- ejection fraction
- aortic valve replacement
- aortic valve
- transcatheter aortic valve replacement
- end stage renal disease
- left ventricular
- early onset
- chronic kidney disease
- coronary artery disease
- minimally invasive
- prognostic factors
- newly diagnosed
- peritoneal dialysis
- acute coronary syndrome
- drug induced
- heart failure
- atrial fibrillation
- patient reported outcomes